May 10th 2024
Updated data from the phase 2 TAMARCK study continued to show safety and preliminary efficacy with the B7-H3–targeting antibody-drug conjugate vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Urology Times 50 Innovations Series: Urinary molecular biomarkers in prostate cancer
July 6th 2022“Our ability to develop innovative technologies and approaches continues to evolve. We have newer molecular profiling techniques that are being applied to urine at the moment,” says Simpa Salami, MD, MPH.
Genetically-adjusted PSA may address overdiagnosis/overtreatment issues of prostate cancer screening
April 11th 2022Results shared during the 2022 AACR Annual Meeting suggested that genetic adjustment of prostate-specific antigen may reduce overdiagnosis of prostate cancer, de-escalate invasive testing, and improve the detection of aggressive disease.
Dr. Spiess discusses differences in MTAP incidence and deletion across various tumors
March 4th 2022“We need to look at tumors a little bit differently. Not so much put them in the same categories, but really look at them based on whether the mutation is as identified in that specific marker,” says Philippe E. Spiess, MD, MS, FRCSC, FACS.
The value of hereditary cancer risk assessment in the community urology practice setting
March 3rd 2022At the 2022 ASCO Genitourinary Cancers Symposium, Neal D. Shore, MD, FACS, presented findings of the prospective study, "Hereditary cancer risk assessment in the community urology practice setting."
FDA approves companion diagnostic for pembrolizumab in MSI-H solid tumors
February 22nd 2022The emergence of tumor-agnostic approvals, such as pembrolizumab for MSI-H solid tumors, has increased the significance of genomic profiling in urology, as patients with prostate, bladder, or kidney cancer may benefit from these therapies.
Lack of guidelines creates high rates of missed Lynch syndrome diagnosis in UTUC
February 22nd 2022“We found that while the NCCN guideline for Lynch syndrome is highly specific in identifying patients with Lynch syndrome, it missed about 50% of patients with upper tract cancer who had Lynch syndrome,” says Hong Truong, MD.
PARP inhibitor niraparib shows promise in mCRPC with DNA repair gene defects
February 10th 2022“Such findings underscore the need for and importance of molecular testing to inform management along with continued research to establish treatment paradigms with appropriately targeted therapies for patients with prostate cancer,” the authors wrote.